Truist analyst Richard Newitter lowered the firm’s price target on Zimmer Biomet (ZBH) to $113 from $118 and keeps a Hold rating on the shares.

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Zimmer Biomet Holdings (ZBH – Research Report), with a price ...

Zimmer Biomet shares at $105 reveal value at 13 times adjusted earnings, as the company continues to grow despite a GLP-1 ...

Medical device company Zimmer Biomet (NYSE:ZBH) will be reporting earnings tomorrow before market hours. Here’s what investors should know. Zimmer Biomet beat analysts’ revenue expectations by ...

Zimmer Biomet posted fourth-quarter revenue growth of 5% in constant currency, which is generally consistent with the preceding quarters in 2024. Why it matters: As Zimmer Biomet has pursued a ...

Please go ahead. Thank you, Operator, and good morning, everyone. Welcome to Zimmer Biomet Biomet's fourth quarter 2024 earnings conference call. Joining me on today's call are Iwan Tornos ...

Zimmer Biomet to acquire Paragon 28 for $13/share, totaling $1.2B in enterprise value. Deal expected to close in H1 2025, with potential $1/share CVR based on 2026 sales milestones. Brand New ...

On Thursday, Zimmer Biomet Holdings, Inc (NYSE:ZBH) reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the Street estimates of $2.30. The orthopedic giant reported ...

Zimmer Biomet provided 2025 guidance of constant currency revenue growth between 3%-5% and adjusted EPS in the range of $8.15 to $8.35. These projections exclude the impact of the Paragon 28 ...

(Reuters) - Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit below Wall Street estimates on Thursday, as it anticipates a hit from a strong dollar. The company expects ...